Clinical Trials Directory

Trials / Completed

CompletedNCT05248100

Rudi Kundini, Pamoja Kundini: Phase I

Strengthening the Continuity of HIV Care in Tanzania With Economic Support: Phase I

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
567 (actual)
Sponsor
University of California, Berkeley · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This protocol describes a 2-arm cluster, randomized controlled trial designed to test the effectiveness of a conditional cash transfer on viral suppression at 6 months among people living with HIV infection (PLHIV) in Tanzania who have disengaged from HIV care. Randomization will take place at the clinic level (HIV primary care clinics). The comparison group receives standard of care standard of care HIV tracing services according to Tanzania's National Guidelines for the Management of HIV and the Ministry of Health to locate potential participants, including home based care (HBC) tracing of PLHIV who have disengaged from primary care, the provision of counseling to return to HIV care, and the offer to schedule an HIV primary care appointment on the spot. Eligible adult PLHIV disengaged from HIV care and living in an intervention facility catchment area will receive the same standard of care HIV tracing and clinical services as control participants, plus the opportunity to receive a one-time cash transfer incentive, conditional upon confirmed completion of a clinical visit if within 90 days of study enrollment. The primary endpoint is viral suppression (\<1000 copies/ml) at 6 months after study enrollment.

Detailed description

The overall objective of this study is to evaluate the effectiveness of a home visit plus one-time financial incentive on the proportion of out of care PLHIV with viral load suppression (\<1000 copies/ml) at 6 months after study enrollment. We will use a cluster, randomized controlled trial design with a sample size of 20 PLHIV in each of the 32 health facility catchment areas (N=640 PLHIV total) to examine the effect of a home visit plus one-time financial incentive on the primary outcome of viral suppression at 6 months. The study will take place across Geita and Kagera Regions (Lake Zone) in Tanzania. This study will follow standard of care HIV tracing services according to Tanzania's National Guidelines for the Management of HIV and the Ministry of Health to locate potential participants, including home based care (HBC) tracing of PLHIV who have disengaged from primary care, the provision of counseling to return to HIV care, and the offer to schedule an HIV primary care appointment on the spot. Eligible and consenting participants living in an intervention health facility catchment area will receive the same standard of care HIV tracing and clinical services as control participants, plus the opportunity to receive a one-time incentive of 22,500 TSH (\~$10 USD), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment. Primary Endpoint: 1\. Viral suppression (\<1000 copies/ml) at 6 months after enrollment Secondary Endpoints: 1. Viral suppression at 12 months after enrollment 2. Durable viral suppression at 12 months after enrollment 3. Appointment attendance 4. Time to re-linkage to care 5. Mortality at 12 months after enrollment 6. Re-linkage to care at 12 months after enrollment 7. Retention at 6 and 12 months, defined as the proportion of PLHIV on antiretroviral therapy (ART) at 6 months after enrollment and 12 months after enrollment, respectively

Conditions

Interventions

TypeNameDescription
BEHAVIORALConditional Cash TransferThe intervention is a one-time cash transfer of 22,500 Tanzanian Shillings (\~$10), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment.

Timeline

Start date
2022-07-13
Primary completion
2024-07-12
Completion
2024-12-03
First posted
2022-02-21
Last updated
2025-07-30

Locations

2 sites across 1 country: Tanzania

Source: ClinicalTrials.gov record NCT05248100. Inclusion in this directory is not an endorsement.